Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Abbott (ABT) to $134 from $138 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $131 from $140 at BTIG
- Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
- This Leading Pharma Company Has Grown Its Dividend 70% Since 2020
- Wall Street’s 3 Safe Bets as Fed’s Powell Downplays Stagflation, But Sees ‘Some Tension Between the Goals’
- Abbott Finalizes Exact Sciences Acquisition, Expands Cancer Diagnostics